Nls Pharmaceutics LTD Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
League Jinn Sarl and Julien Ruggieri have reported a combined beneficial ownership of 21.6% of NewcelX Ltd.'s common shares.
Clover Wolf Capital and Adi Wolf have jointly reported a 7.5% passive ownership stake in NewcelX Ltd., holding 343,120 common shares.
Biotechnology Value Fund and its affiliates reported a beneficial ownership of 0.6% in NewcelX Ltd. common shares.
Lind Global Fund II LP, along with its affiliates, has filed an amendment to its Schedule 13G, reporting a passive beneficial ownership of 4.9% in NLS Pharmaceuticals Ltd. as of December 31, 2024, indicating a reduction from a previous stake.